GET DAILY SIGNALSMerit Medical Systems (MMSI) Delivers Solid Q3 2026 Results with Raised Guidance
Key Takeaways
- Merit Medical Systems (MMSI) reported third-quarter 2026 revenue of $416.2 million, up 8.4% year over year, with organic constant currency growth of 9%.
- Non-GAAP earnings per share (EPS) came in at $1.12, ahead of the roughly $1.04 per share consensus estimate, while GAAP EPS was $0.70.
- Non-GAAP operating margin expanded to 21.3% from 19.7% in the prior-year quarter, while GAAP operating margin rose to 14.1% from 11.1%.
- Management raised full-year 2026 guidance, now projecting revenue of $1.635–$1.642 billion and non-GAAP EPS of $4.33–$4.37.
- The company also disclosed the acquisition of Solo Pace, Inc. for approximately $45 million, completed on October 13, 2026.
Earnings Context and Why It Matters
Merit Medical Systems (MMSI) is a global manufacturer of healthcare technology and disposable medical devices used across cardiology, radiology, oncology, and endoscopy. Its third-quarter report matters because it tests whether the company can sustain the momentum built in the first half of 2026, when stronger-than-expected results prompted management to raise its full-year outlook. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors are watching how Merit balances organic growth with recent acquisitions and the divestiture of its DualCap product line, while managing tariff-related cost pressure. A 9% organic constant currency growth rate signals durable underlying demand, and the raised guidance suggests confidence in the balance of the year.
Reported Results
Merit Medical Systems (MMSI) reported third-quarter 2026 revenue of $416.2 million, an increase of 8.4% on a reported basis. Constant currency revenue rose 8%, while constant currency organic revenue rose 9%. Non-GAAP net income was $67.4 million, or $1.12 per share, compared with $54.9 million, or $0.92 per share, in the prior-year period. GAAP net income was $42.3 million, or $0.70 per share, up from $27.8 million, or $0.46 per share, a year earlier.
Profitability improved across both measures. Non-GAAP operating margin reached 21.3%, up from 19.7% in the third quarter of 2025, while GAAP operating margin climbed to 14.1% from 11.1%. The company ended the quarter with cash and cash equivalents of $503.6 million and total debt obligations of $747.5 million, with roughly $697 million in available borrowing capacity.
Management also updated its full-year 2026 guidance, now expecting revenue of $1.635–$1.642 billion and non-GAAP EPS of $4.33–$4.37, an increase from the prior guidance of $1.631–$1.643 billion in revenue and $4.25–$4.35 in non-GAAP EPS.
Market Reaction and Investor Sentiment
Heading into the report, shares of Merit Medical Systems (MMSI) had been trading near record levels, reflecting elevated expectations after two consecutive quarters of beats. Analysts had projected roughly $1.04 per share in earnings on about $410 million in revenue, and the company's reported non-GAAP EPS of $1.12 and revenue of $416.2 million came in above those marks. The combination of accelerated organic growth, expanded operating margins, and a raised full-year outlook provided a positive signal to investors, though tariff uncertainty and the integration of recent acquisitions remain key watchpoints that could influence sentiment going forward.
Forward Outlook and Key Factors to Monitor
Merit Medical Systems (MMSI) enters the final stretch of 2026 with raised full-year targets and several catalysts worth watching. The updated guidance calls for full-year revenue growth of about 8% and non-GAAP EPS growth of 13% to 14%, implying management expects momentum to continue into the fourth quarter.
One area to monitor is margin durability. The company's profitability improvement has been supported by pricing, product mix, and manufacturing efficiencies, but these gains must be weighed against ongoing tariff exposure and any input-cost volatility. Investors will also want to track how newly acquired businesses, including Solo Pace and earlier additions such as View Point Medical, contribute to organic and inorganic growth without diluting near-term profitability.
Balance sheet strength provides flexibility for further strategic activity, given cash of more than $500 million and available borrowing capacity of about $697 million. At the same time, integration execution across multiple recent acquisitions will be a key test of management's ability to sustain both growth and margins. As Merit builds toward its long-term strategic plan, the focus remains on whether it can convert strong top-line performance into consistent profitability and cash flow.
Using AI Tools for Deeper Research
In my own workflow, I frequently rely on Tickeron’s AI Screener to quickly scan for comparable names in healthcare and review technical and fundamental filters side by side. It has become a useful step when evaluating results like those from Merit Medical Systems (MMSI) against peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MMSI in upward trend: price rose above 50-day moving average on October 15, 2026
MMSI moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 27 of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on MMSI as a result. In 54 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for MMSI just turned positive on October 12, 2026. Looking at past instances where MMSI's MACD turned positive, the stock continued to rise in 22 of 36 cases over the following month. The odds of a continued upward trend are 61%.
The 10-day moving average for MMSI crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +3.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where MMSI advanced for three days, in 198 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The 10-day RSI Indicator for MMSI moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 19 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MMSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
MMSI broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. MMSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MMSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.320) is normal, around the industry mean (5.000). P/E Ratio (38.118) is within average values for comparable stocks, (37.535). Projected Growth (PEG Ratio) (1.574) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.273) is also within normal values, averaging (56.876).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What are Household Expenses?
What is the Head-and-Shoulders Top (Bearish) Pattern?
The Rise of AI in Algo Trading: A Glimpse into Financial Learning Models
What Is the Williams Alligator Indicator and How Do You Trade It?
Why NVIDIA May Lose China Sales but Win the AI Battle: Short and Long Term Considerations
General Information
a manufacturer of disposable medical products
Industry PharmaceuticalsOther
Advertisement